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ABSTRACT 
 
Group B Streptococcal (GBS) infections pose a great threat to mortality in 
neonates. Neonates are often exposed to GBS both before, during, and after delivery, 
which can cause a range of health problems including meningitis, sepsis, or stillbirth. One 
of the major virulence factors that contributes to the infectivity of the pathogen is the 
bacterial capsule. The capsule is a polysaccharide matrix surrounding the cell which 
helps in the evasion of host defenses, and penetration into normally sterile sites like the 
bloodstream. The highly conserved GBS protein CpsA has been shown to regulate 
expression of the capsule. The objective of this study is to explore protein-protein 
interactions with CpsA, as well as truncated versions of CpsA, using co-
immunoprecipitation protocols to identify CpsA binding partners. Modified CpsA strains 
with a maltose binding protein (MBP) tag allow for specific selection of target protein 
using antibodies to that tag. Research has previously shown that deletion of the LytR 
domain, one of two extracellular domains that follows three membrane-spanning domains 
on the N-terminus, has a negative impact on capsule production, indicating an 
extracellular binding occurrence in this domain. Further evidence shows that a portion of 
the extracellular domain potentially binds at the septum of the cell, however the specifics 
of this interaction remain unknown. Therefore, extracellular interactions may be playing 
a role in capsule production and attachment to the cell wall. By demonstrating an 
interaction with other proteins, further targets could be identified for treatment of GBS 
infection.
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 1 
BACKGROUND AND INTRODUCTION 
 
Background 
 Group B Streptococcal (GBS) infections pose a great threat to mortality in 
neonates. Newborn children often face GBS infections, which can cause a range of health 
problems including meningitis, sepsis, and stillbirth. One of the major virulence factors 
that corresponds to the success of the bacteria as a pathogen is the bacterial capsule, a 
polysaccharide matrix surrounding the cell, which helps in the evasion of host defenses, 
and penetration deeper into normally sterile sites like the bloodstream. The highly 
conserved GBS protein CpsA has been shown to regulate expression of the capsule [1]. 
This protein contains a number of intracellular and extracellular domains, some of which 
are of unknown function. Studies have shown that the presence or absence of certain 
extracellular domains of CpsA correlate to the capsule level of the cell, leading 
researchers to believe that CpsA plays a role in capsule regulation. To better understand 
infections caused by GBS and to further improve methods of treatment, the mechanism of 
CpsA is currently being researched, as it may provide clues or targets for future treatment 
options. In this introduction, the background of GBS infections will be explored, as well 
as the role that the polysaccharide capsule plays in those infections. Current research into 
CpsA functionality will be also discussed, with possible links to capsule regulation.  
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Streptococcus agalactiae 
 
 GBS infections arise as a result of exposure to Streptococcus agalactiae. This 
bacterium often resides within the human vaginal and rectal mucosa as a commensal 
organism and does not normally cause infection in healthy individuals. The issue of GBS 
infection does arise, however, in infants and immunocompromised adults, as these 
bacteria are opportunistic pathogens. GBS infections serve as a major cause of concern 
for both newborns, and infants under three months of age [2]. After this age, the 
prevalence of infection decreases significantly so it is of great importance to find 
treatment and preventative measures that will be targeted towards pregnant mothers, and 
newborn children. GBS is the leading cause of meningitis and sepsis in infants and is also 
a cause of premature birth and stillbirth when infection occurs in neonates [1]. As is 
apparent, GBS infections pose a significant threat to neonates, and infants alike. It is not 
the goal of this paper to discuss the prevalence and specifics of GBS infections, but some 
background into the infection is important to understand why the biochemical features 
that will be discussed later matter in context to this topic. Current preventative measures 
to prevent infection include intravenous antibiotic treatment to women in labor and 
delivery that test positive for GBS in an effort to prevent the bacteria from infecting the 
newborn as it passes through the birth canal. This treatment has proven effective in 
reducing incidence of GBS infection within the first week of life, however, has not had 
an impact on later infections that occur within the first three months after birth [1]. There 
are currently no effective treatments for infections that range outside of standard 
antibiotic treatment. Current research revolves around regulation of the polysaccharide 
capsule that is characteristic of GBS, as well as many other Gram-positive pathogens.  
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Polysaccharide Capsule 
 
 The polysaccharide capsule that exists extracellularly is a key factor in bacterial 
survival and dissemination into the host. This capsule is a decoration of sugars that coat 
the outside of the cell (Fig. 1). These sugar polysaccharides are attached covalently to the 
peptidoglycan layer on Gram positive cell walls and are specific to this type of bacteria 
[3]. The function of this capsule has been shown in studies to directly impact the ability 
of the bacteria to survive, and to disseminate into a host. Studies performed on 
Streptococcus iniae demonstrated that when the capsule levels were reduced, fish 
infected with S. iniae were able to clear the infection and survive, as opposed to fish 
infected with the wild type bacteria, which showed a high mortality rate [4]. Studies into 
the capsule have also shown that its regulation is highly linked to immune system 
evasion, and by altering the capsule the bacteria is able to “hide” from host defenses, 
allowing it to penetrate deeper into the cell, and avoid being culled by the host [5]. The 
genes responsible for encoding and regulating the polysaccharide capsule in S. iniae are 
highly conserved in GBS as well, leading to a very similar result in GBS infections. The 
GBS capsule has been linked directly to immune evasion, and bacterial survival in the 
bloodstream, allowing it to penetrate deeper and into normally sterile sites [1]. The result 
of this is an opportunistic pathogen that is able to travel up the vaginal canal and infect 
the uterus, resulting in neonatal GBS infection. As these studies show, the polysaccharide 
capsule acts as a main virulence factor that results in increased pathogenicity of the 
bacteria, in this case GBS. In order to then understand how the cell regulates this capsule, 
the DNA encoding the capsule and capsule regulatory genes must be explored. 
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Gram-positive cell wall diagram 
 
Figure 1. A simplified diagram of the gram-positive cell wall. In this view, LM 
corresponds to the lipid layer, PG corresponds to the peptidoglycan, LTA and WTA to 
teichoic acids, and CPS to capsule polysaccharide on the exterior of the cell. [5] 
 
Streptococcus capsule operon 
  
Figure 2. Operons corresponding to capsule regulation in S. iniae, and S. agalactiae 
(GBS). The operons are aligned based on the initial promoter, with genes labeled and 
segmented to show their length. [7] 
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Capsule Operon 
 
The capsule operon is found to be highly conserved in a number of Streptococcus 
genus members. The first gene on this locus is cpsA (cps denotes the locus name) (Fig. 
2). This specific gene is conserved in all three Streptococcus bacteria discussed 
previously (Fig. 2), and is conserved across all GBS serotypes, as well as a number of 
other Gram-positive bacteria [1]. This gene encodes the CpsA protein, the protein that 
has been the main focus of studies surrounding Gram positive capsule control, and the 
main focus of research in the Neely lab at the University of Maine. The CpsA structure in 
GBS has an intracellular N-terminal domain, three transmembrane domains, and a larger 
extracellular portion including the C-terminal domain (Fig. 3). The extracellular domain 
is broken into an accessory domain, which occurs right after the last transmembrane, and 
is followed by a LytR domain (Fig. 3). These two domains are connected by a small 24 
amino acid peptide region of uncharacterized structure. To analyze the structure of this is 
to then delve into the particular mechanisms of each of the domains, some of which are 
more extensively understood than others. Although a singular protein, the separate 
domains of CpsA all appear to control relatively different functions all relating to the 
cellular polysaccharide capsule regulation. A note: the evaluation and discussion 
surrounding the CpsA protein will center around the GBS CpsA, although it does exist in 
a number of bacteria and this introduction will include references from studies outside 
GBS. Any mention of CpsA outside of GBS or any portion of that protein will be 
explicitly stated, otherwise it may be assumed that it is being discussed in context to 
GBS. 
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CpsA Protein Structure 
 
Figure 3. Physical protein structure of CpsA as shown embedded within the cell 
membrane. Intracellular and extracellular portions of the protein are labelled, with 
transmembrane domains highlighted as well. [6] 
 
Intracellular CpsA Domains 
 
To begin, the intracellular N-terminal domain of CpsA, will be discussed. This 
small cytoplasmic region of CpsA has been shown to be conserved in GBS serotypes, as 
well as other Gram-positive bacteria CpsA proteins, as well as the closely related LytR 
proteins (which will be discussed later, as this is a domain in CpsA) [6]. Function of this 
region is not completely understood; however, it does contain a DNA binding region (8). 
This region is able to bind its own promoter through the usage of positively charged 
amino acids located near the N-terminus, which promotes binding with the negatively 
charged DNA backbone [8]. Other studies conducted on both GBS and Streptococcus 
pneumoniae CpsA indicate the presence of a leucine zipper motif extending from the first 
transmembrane domain into the cytoplasm of the cell, which is commonly associated 
with DNA binding through dimerization [6]. This result would support that of the 
intracellular N-terminal domain binding the cpsA promoter and helping promote its own 
expression. However, BLAST alignment of the GBS cpsA promoter with the S. iniae 
cpsA indicate no sequence similarity even though the proteins encoded by the cpsA gene 
in both bacteria share large amounts of amino acid identity [6]. Furthermore, the leucine 
 7 
zipper mentioned previously was also shown to be lacking the predicted coiled-coil 
sequence that is commonly associated with that domain, and assists in the DNA binding, 
so a functional leucine zipper motif requires further validation [6]. Despite the 
differences that arise, the GBS CpsA does bind with DNA, albeit with a more unknown 
mechanism than that of other Streptococcus bacteria due to the lack of a functional 
leucine zipper motif. Electrophoretic Mobility Shift Assay (EMSA) data were used to 
confirm this binding [6]. Results from the same study mentioned above indicate that the 
N-terminus of CpsA located in the cytoplasm is required to bind to DNA, however the 
interaction may be mediated by the transmembrane and extracellular domains in a yet 
uncharacterized manner [6]. 
 
Previous Research 
 
 Next, it is important to look at the extracellular domains of CpsA. These are the 
domains where current research is highly concerned with understanding how the two 
domains, accessory and LytR (Fig. 3), function to regulate the polysaccharide capsule, 
play a role in its attachment, and possibly play a role in division at the cell septum. In 
order to do so, studies will be discussed that explore truncated models of CpsA, and 
associate that with capsule production, and virulence. 
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Cps2A Structure as seen in Streptococcus pneumoniae 
 
Figure 4. Crystal structure of the extracellular domains of Cps2A as it is found in S. 
pneumoniae. This is the only crystal structure that exists for CpsA, and although this 
model of for S. pneumoniae, it is homologous with GBS. This structure indicates the two 
distinct domains of this region, the Accessory domain (purple) and the LytR domain 
(green). [9] 
 
Before diving into the current research surrounding these extracellular domains, it 
is important to understand the physical structure that both the accessory, and LytR 
domains exist in outside of the cell. The one crystal structure that does exist for one of the 
CpsA homologs (Fig. 4) shows two distinctly folding domains, with the accessory 
domain in purple, and the LytR domain in green. They are connected by a single peptide 
region that was determined to be unstructured and of constantly changing conformation. 
From there, the crystal structure reveals an active site within the LytR domain 
(characterized by yellow within the green structure), and an abundance of alpha helices in 
both structures. Now that this crystal model has been presented to help understand the 
protein, the primary data set that contributes to the research being undertaken in order to 
understand the function of these two domains can now be presented. A preface to this 
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data is that there exists a somewhat understood function in other organisms, especially 
the green LytR domain (Fig. 4), but not as much so with the accessory domain. However, 
in GBS they remain largely unknown except for a host of processes surrounding the 
capsule in which they appear to play a role. The specific interactions of this process 
remain unknown. A primary data set constructed from truncated CpsA in GBS is a 
starting point to understanding the role that this protein plays in capsule regulation. 
 
Capsule Level Comparison Across CpsA Variants 
 
Figure 5. Buoyant density measurements of the capsule produced by GBS strains 
containing 1) The wild type plus an empty vector control 2) A GBS strain lacking CpsA 
and containing an empty vector control 3) The wild type GBS with a vector containing a 
truncated CpsA that only contains the accessory domain plus the connecting peptide and 
no LytR domain 4) The wild type GBS plus an empty vector plus a peptide encoding the 
region between the accessory and LytR domains and 5) Wild type GBS plus an empty 
vector plus a scrambled peptide meant to mimic the connecting peptide seen in 4. Results 
seen here indicate reduced capsule level when the truncated CpsA was added in 
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conjunction with the wild type protein. When CpsA was removed entirely there is still 
reduced levels of capsule. When only the 24 AA peptide region was added with the wild 
type protein there was still a reduction seen in the capsule levels that was not seen when a 
scrambled peptide of the same length was added instead. [1] 
 
 The major point of the study that led to current understanding of CpsA function in 
GBS infection is that the CpsA protein is playing a large role in polysaccharide capsule 
levels. This study set a baseline for wild type protein containing an empty vector as a 
control, then modified the genome such that CpsA was removed, and a truncated version 
of CpsA was added on a plasmid that contained only extracellular domains up through 
the connecting region of the accessory domain and LytR domain. The LytR domain was 
removed in its entirety. This study showed that addition of a plasmid containing no LytR 
region of CpsA, when added to bacteria containing wild type CpsA, was able to 
significantly reduce capsule levels of the cell (Fig. 5) [1]. This is significant in that it not 
only implies that CpsA plays a major role in the regulation of the polysaccharide capsule 
of GBS, but also that a dominant negative phenotype would occur when complemented 
with the wild type protein. It was hypothesized that this is either through binding of the 
truncated and wild type proteins together, causing them to both lose function, or through 
the truncated protein still binding at target sites, and blocking activity of the wild type 
protein [1]. This study also showed that addition of a 24 amino acid peptide which 
matched the C-terminal end of the accessory domain inhibited the wild type protein and 
resulted in slightly decreased capsule levels, as well as longer chains of cocci indicating a 
change in regulation of cell division (Fig. 6) [1]. Further research indicated a collection of 
truncated CpsA proteins, as well as the added peptide, bind at the cell septum which 
 11 
further implicates CpsA in playing a role in cellular division [1]. Synthetic peptides with 
a fluorescent component were visualized using confocal microscopy as bound at the cell 
septum [1]. 
 
GBS Chain Length Measurement Under Variant Conditions 
 
Figure 6. Phase contrast microscopy of overnight cultures of wild-type GBS when grown 
in the presence of just protease inhibitors (A) and in the presence of the CpsA peptide as 
well as protease inhibitors (B) indicating longer chains when the peptide was added to the 
culture. [1] 
 
Although CpsA in GBS is the primary focus of this introduction, a slight 
deviation must be made. Because this protein is so highly conserved and some domains 
are seen in a large number of Gram-positive pathogens, this slight deviation will be made 
to discuss the LytR domain of CpsA in GBS as it is seen in alternative pathogens. One 
example of this is the LytR-CpsA-Psr (LCP) enzymes seen in Staphylococcus aureus. 
Studies have shown that this enzyme in S. aureus is responsible for the direct attachment 
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of secondary cell wall polymers (capsule) to the peptidoglycan through discrete linkages 
[10]. This same study reports that although closely involved near the pathways that are 
responsible for synthesis and transport of the polymers, the LCP enzyme itself plays a 
role in the actual attachment once the polymer is on the exterior of the cell surface. A 
deeper look into the mechanism behind this action led to a proposal that LCP proteins 
catalyzed the transfer of undecaprenyl phosphate-linked secondary cell wall polymer 
intermediates onto the amino acid sugars of the peptidoglycan [10]. However, despite 
evidence to support this claim, preliminary data do not confirm this function entirely. 
Further functional studies need to be performed as right now the only data that exists is 
structural and genetic data [9]. This does, however, remain the most up to date 
mechanism proposed for this process. Relating back to CpsA in GBS, this mechanism is 
likely similar to that of the LytR domain. That is due to the fact that these structures are 
highly conserved, and the LCP of S. aureus is closely related to LytR. Interestingly, the 
LCP enzymes do not contain the accessory domains that are seen in CpsA in 
Streptococcus [9].  
 The last aspect of background information from LCP enzymes in bacteria other 
than GBS, is the aspect that relates these enzymes to normal septum formation and the 
role they possibly play in cellular division. Studies performed on S. pneumoniae indicate 
that the LytR domain is one that interacts at the cell septum and plays an unknown role in 
cell division. Electron microscopy results indicate that mutant cells with LytR removed 
(ΔLytR) were unable to divide normally and growth was stunted when mutant growth 
was compared over a period of cell growth (Fig. 7) [11]. Although this observation was 
made that strongly hints towards an LCP interaction at the cell septum, the exact 
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mechanism of this interaction remains unknown. It is unknown what the enzyme is 
specifically binding to at the cell septum, and how this contributes to the cell separation 
during division. This study is the first one to explore this interaction. Further information 
in this study revealed that the loss of LytR led to an increase in cell autolysis [11]. No 
further information exists on the specifics of this mechanism in S. pneumoniae, or in 
GBS. The final information that this study revealed was that a LytR deficient strain was 
able to be complemented back to a higher growth rate when a LytR plasmid was 
introduced, however could not be complemented back to original strength of the wild 
type bacteria [11]. This hints to the fact that there may be a suppressor mutation in one of 
the strains used in the study resulting in a null effect from the introduced plasmid. This 
could explain the inconsistency in their data from the complemented sample, and not be a 
result of the mutation (Fig. 7). This is an important distinction when examining their data, 
as this serves as a control for further applications of this assay, so must be mentioned. 
 
Growth Density Comparison of Truncated CpsA Strains  
A B 
Figure 7. Growth density of ΔLytR mutated cells measured at 492nm (A) with white 
square being with LytR but without a downstream alternate promoter which should have 
no effect, black square being ΔLytR but complemented with a plasma LytR, black 
diamond being similar to black square but with backcross, white triangle being ΔLytR 
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and ΔLytA (murein hydrolase gene), and black triangle being just ΔLytR. Individual cells 
of the ΔLytR cells were imaged using transmission electron microscopy (B) and off-
centered cell septum indicative of a malformed cell labeled by an arrow. [11] 
 
As shown from the above studies, the possible cell division mechanism of CpsA 
could help contribute to a target for therapeutic techniques. The CpsA protein can 
ultimately be linked to a multitude of cellular processes that are all vital to the formation 
of a healthy, pathogenic bacterium. It is important to begin to understand ways that it 
may be clinically interrupted in order to help stem the spread of GBS in the host. One 
study performed by Rowe et al. identified that decrease in expressed cellular capsule 
correlated with the ΔLytR mutation of CpsA in GBS which contributed to beginning the 
research towards discovering a possible pathway that could be interrupted in order to 
cease the spread of the bacteria, and ultimately decrease infection rates in infants, and 
other affected populations. By adding a plasmid insert into the coding region of the cpsA 
gene, ensuing capsule production was shown to be significantly lower than that of both 
the wild type, and ΔcpsA strains (Fig. 8) [1]. Assessment of GBS dissemination of GBS 
into model organism zebrafish organs displayed a large decrease in levels when the wild 
type strain was compared to both the ΔCpsA, and cpsA-insert strains (Fig. 8) [1]. 
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Host Dissemination Comparison of Truncated CpsA 
A
B 
Figure 8. Measurement of dissemination into zebrafish spleen, heart, and brain of wild 
type, ΔcpsA, and cpsA-insert strains of GBS (A) and capsule density in these same 
strains (B). When CpsA was removed or modified, a significant reduction in 
dissemination was seen. [1] 
 
 At this point, the current mechanism behind GBS CpsA remains a mystery. 
Although this protein has been implicated to play roles in polysaccharide capsule 
maintenance and cell division, the specific interaction and possible protein binding 
partners remain unknown. Research is currently being undertaken to discover what 
specific role this protein may be playing due to its evidently significant role in the 
pathogenicity of GBS, as well as some other Gram-positive pathogens in which it is 
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conserved. This introduction will move on to discuss the future direction of research 
being undertaken here at the University of Maine regarding CpsA. This research is 
relevant to the background information presented here in that this research is the logical 
next step in elucidating the specific function of this protein in GBS, as well as in highly 
conserved homologs, and understanding how it may be a target for treatment of infections 
caused by GBS, or other Gram positive pathogens. Speculations about the biochemical 
mechanisms suggested by this data can also be explored with connections back to 
relevant information. 
 
Current Understanding of CpsA 
 
Figure 9. A summary of the current understanding of CpsA as it is seen in GBS with the 
intracellular N-terminal containing DNA binding potential, and the extracellular domains 
playing a role in the attachment and regulation of the polysaccharide capsule, and 
possible influence at the cell septum. [No citation, made by me] 
 
The current diagram of understanding which summarizes the current model of 
CpsA in GBS (Fig. 9) is incomplete in that it does not contain any known mechanisms 
and is highly based on singular studies that do not define specific interactions. It is known 
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that the intracellular region of CpsA binds to DNA containing the capsule operon 
promoter [8] but the specific interaction is unknown, and there are a multitude of 
outcomes that could be expected because of this preliminary result. Similarly, although 
the extracellular domains are known to interact with the polysaccharide capsule, the 
specific mechanism of this remains unknown. Due to the link between the pathogenicity 
of GBS and the polysaccharide capsule, these extracellular domains are of high interest to 
researchers that are hoping that disruption of these domains or their binding partners 
could pave the way towards an effective treatment of GBS in infants, and pregnant 
mothers. 
As presented at the beginning of this introduction, the primary virulence factor 
supporting GBS infection is the polysaccharide capsule. This sugar polymer attached to 
the exterior of the cell wall is the primary mechanism through which the bacteria is able 
to avoid the host immune system [5]. With host immune evasion, the pathogen is able to 
penetrate deeper into the body and colonize sites like the spleen, heart, and brain, which 
leads to the cases of infantile meningitis. Understanding the mechanism behind capsule 
synthesis and being able to possibly target it in some way would be key in reducing the 
ability of the pathogen to cross sterile sites like the blood-brain barrier and colonize the 
brain. Additionally, reduction of the capsule would also allow the bacteria to be 
recognized and cleared by the host immune system, barring any sort of 
immunosuppression.  
The major data set that this project pulls from and the focus of the ongoing 
research at the University of Maine is the ΔCpsA and ΔLytR capsule level measurements 
(Fig. 5) as conducted in the Neely lab. Their results indicated that a truncation of the 
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CpsA protein resulted in significantly reduced capsule levels in GBS, and even more so 
when a truncated version of CpsA was introduced on a plasmid into a wild type 
bacterium [1]. This was an interesting result in that it implies the truncated CpsA is able 
to compete with the full-length protein, and inhibit its binding resulting in a dominant 
negative phenotype. Although the mechanism again remains unknown, based on this 
result it can be inferred that it is through one of two major pathways. The ΔLytR 
truncated CpsA may be binding together with the full-length protein and causing it to be 
inactivated through blocking of its binding site, and inhibition of its enzymatic activity. 
This would result in lack of capsule due to the presence of all the correct protein 
precursors, but no ability of the CpsA to catalyze or be involved in the attachment to the 
cell surface and the formation of the polysaccharide capsule. The other possible 
mechanism that may be the cause of this apparent dominant negative phenotype would be 
that the truncated CpsA is binding to the sites on the polymers or on the cell surface that 
the full length CpsA binds to, resulting in inhibition of its attachment and subsequent 
activity. This would also result in the same lack of capsule expression, albeit through a 
slightly different mechanism. The distinction between these two possible mechanisms is 
important due to the fact that any possible GBS therapies would likely revolve around 
this specific interaction and knowing the exact mechanism would be required in order to 
pursue new treatment options or antibiotics.  
A subset of this research is the fact that the GBS CpsA contains an additional 
accessory domain on the extracellular portion. This accessory domain is not found in 
other CpsA homologs in non-Streptococcus bacteria. As shown in the crystal structure 
(Fig. 4) this region folds entirely independent of the LytR domain. Although the 
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mechanism of the LytR domain is still unknown, research on this domain (LCP enzymes) 
has been ongoing, and the general scheme of this domain is somewhat understood, with it 
playing a specific role in the attachment of the sugar polymer to the peptidoglycan in 
order to create the polysaccharide capsule [10]. This is likely similar for the LytR domain 
in GBS CpsA; however, the accessory domain is a novel domain with no near relatives 
with characterized function. Because of this, it is a target then for future research as it 
may mediate this process in a way unseen in other bacterial CpsA strains. It is too early to 
speculate as to what this function may be, as there are no data published at the time of 
this writing. However, novel research being performed by the Neely laboratory at the 
University of Maine is hoping to uncover that function, as well as that of LytR, and 
elucidate a mechanism of this extracellular domain.  
 
Research Objective 
 
In conjunction with the research concerning the function of the accessory domain, 
a primary study around the function of the CpsA LytR domain is being undertaken in the 
same lab. This research is detailed here as part of my honors thesis. The aim of this 
research is to understand how the LytR domain specifically is interacting on the cell 
surface, to help elucidate the mechanism of action for enzymatic activity concerning the 
attachment of the sugar polymer to the cell wall to form the polysaccharide capsule. The 
focus of this study is on analysis of protein-protein interactions with the CpsA protein 
and using modified versions of the protein in order to coimmunoprecipitate binding 
partners.  
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 The truncated model of CpsA without the LytR domain, denoted CpsA-ΔLytR, 
will be used in order to determine partners that bind to CpsA without LytR, and 
compared to data describing binding partners that bind to CpsA wild type. By comparing 
the data, proteins that interact specifically with the LytR domain can be identified. Two 
assays, an in vivo and an in vitro, were attempted in order in order to find these binding 
partners. The in vivo assay, performed by isolating the MBP tagged CpsA-ΔLytR 
expressed in GBS, can be used to assess binding partners from the living cell. The in vitro  
assay, performed by isolating MBP tagged CpsA-ΔLytR from a modified E. coli strain, 
then incubating with GBS lysate, can be used to assess binding partners that occur 
without the presence of a functioning membrane, and when the CpsA is not embedded in 
the membrane as it is naturally. The purpose of this variation is to eliminate any 
possibility that proteins are missed due to being embedded in the cell membrane. 
 The goal of this study was a concrete list of proteins that bind specifically at the 
LytR domain of CpsA. As mentioned above, this protocol has been performed on wild 
type CpsA already as a way to compare. This previous data set contains all binding 
partners of CpsA (~ 12 as determined by Mass Spec), which is very important when 
trying to determine function (D.P. and M.N.N., unpublished data). Many of these binding 
proteins have known function and can be linked to concrete cellular mechanisms. When 
data are obtained from these assays run with CpsA-ΔLytR, the coimmunoprecipitated 
proteins will not contain any that bind specifically to the LytR domain, therefore showing 
from the previous data which proteins are only interacting with this domain. This is the 
logical next step in CpsA research, as the function can begin to be understood when its 
interacting partners are known. Similarly, by understanding where this protein interacts it 
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is likely that new therapies and treatments specific towards GBS could be discovered or 
created, as knowing how to specifically interrupt CpsA would result in attenuated 
virulence as previous results have shown.  
 
MATERIALS AND METHODS 
 
 
A Note 
 
Due to the nature of this project, methods described here provided starting points for 
all of the assays attempted. Many iterations occurred that deviated from the listed 
protocol, however the details of such changes will be noted in the results and discussions 
section of this paper. 
 
Overnight bacterial culturing and sub-culturing 
 
In preparation for lysis and protein isolation, Escherichia coli TOP10 strains were 
grown overnight aerobically in a 37°C water bath with constant agitation. Frozen 
bacterial strains were inoculated into LB (Luria Bertani) broth and supplemented with 15 
µg/mL Chloramphenicol. GBS strains were grown in Todd-Hewitt yeast broth (ThyB) 
overnight at 37°C without shaking and supplemented with 3 µg/mL Chloramphenicol. 
When sub culturing, bacteria were grown overnight for no more than 15 hours. Overnight 
samples were then added to new media supplemented with Chloramphenicol (to the same 
amount as the overnight cultures) in a ratio of 1:100. Subcultures were incubated in the 
same environment as the overnights until they measured 0.4 to 0.6 at OD600. Varying 
volumes of subculture were used. 
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Sonication 
 
Samples to be sonicated were aliquoted into 5mL polypropylene tubes. The sonicator 
was moved into the chemical hood with foot petal attachment leading to the floor. All 
samples were kept capped and on ice in the chemical hood. Prior to use, 70% ethanol was 
used to sterilize the sonicator probe. Samples were uncapped and sonicated at the power 
level 8, while held in a beaker of icy water, for 30 seconds, followed by a 30 second rest. 
This process was repeated until the desired amount of time of sonication had elapsed. The 
end of the sonicator was sanitized prior to each new sample. 
 
Chemical lysis of E. coli and GBS 
 
Two main chemical solutions were used to lyse both E. coli and GBS cells in 
conjunction with sonication (see results). E. coli cells were pelleted via centrifugation and 
resuspended in lysis solution (volumes varied) (50mM Tris-HCl, 150 mM NaCl, 1% 
Sodium lauroyl sarcosinate [wt/vol], 1% Triton X-100 [vol/vol], 10 mM 3-[(3 
Cholamidopropyl) dimethylammonio]-1-propanesulfonate [CHAPS], and 1 cOmplete 
Mini EDTA-free Protease Inhibitor Cocktail tablet [Sigma Aldrich]) and incubated at 
37°C. GBS cells were pelleted via centrifugation and resuspended in 2-10mL of 
lysozyme solution (2.5µL 1U/µL DNAse1, 1 cOmplete Mini EDTA-free Protease 
Inhibitor Cocktail tablet [Sigma Aldrich], 125mg lysozyme, 50µL 5000U/mL 
Mutanolysin, 10mM MgSO4, 1mM CaCl2) and incubated at 37°C. Varying combinations 
of these solutions were used as development of a novel protocol to fully lyse GBS cells 
progressed, however these recipes were not changed over this course. Details on this 
protocol can be found in the Results section. 
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Amylose column protein purification 
 
E. coli lysates were diluted 1:5 in column buffer (Stock solution - 8mL Tris-HCL [pH 
7.4, 0.5M], 1mM EDTA, 26.67mL 1.5M NaCl, ddH2O until 200mL). Amylose resin was 
poured into the 2.5x10cm glass column and washed with 8 column volumes of column 
buffer while at 4°C. Sample lysate(s) then run through the column followed by 12 
column volumes of column buffer to wash. To elute, 30mL of 10mM maltose in column 
buffer was run through, with fractions being collected every 3mL. 
 
ChromoTek MBP Trap bead coimmunoprecipitation 
 
ChromoTek MBP Trap A beads equilibrated by adding 25µL beads into 500µL ice 
cold wash/dilution buffer (ChromoTek). Bead slurry then vortexed at 3000rpm for 2min 
at 4°C. Supernatant was removed and discarded. This wash was repeated twice, and 
beads were suspended in 500µL ice cold wash/dilution buffer. This bead slurry was then 
added to the lysate solution and incubated overnight at 4°C while shaking end over end. 
The following day, the lysate/slurry mixture was centrifuged at 2000rpm for 2 min at 
4°C. The supernatant was discarded, and the beads were washed once using 500µL 
150mM NaCl ice cold wash/dilution buffer. They were then centrifuged again and 
washed two more times using 500µL 500mM NaCl ice cold wash/dilution buffer. The 
slurry was then centrifuged one final time and resuspended in Laemmli sample buffer and 
boiled at 95°C for 10 minutes to elute proteins off of beads. Sample could then be 
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centrifuged and separated into eluent proteins in supernatant and a solid bead pellet to run 
on an SDS-PAGE gel.  
 
Anti-MBP magnetic bead coimmunoprecipitation 
 
New England Biolabs Anti-MBP magnetic beads were [New England BioLabs, 
E8037S] equilibrated by adding 40µL beads into 500µL 0.1M Sodium Phosphate pH 8, 
vortexed, and applied to a magnet to pull beads to the side. Supernatant was removed, 
and beads washed twice. Then, 500µL of lysate was added to beads, and incubated 
overnight at 4°C while shaking end over end. The following day, the beads were applied 
to a magnet, and supernatant removed. Beads were washed 3 times with 500µL 0.1M 
NaP pH 8, and vortexed to mix before magnetization. Beads were then suspended in 4x 
Laemmli sample buffer or PBS and equivalent volume 4x Laemmli sample buffer and 
boiled 85°C for 5 minutes. Sample could then be applied to a magnet and separated into 
eluent proteins in supernatant and a solid bead pellet to run on an SDS-PAGE gel.  
 
SDS-PAGE and Coomassie staining 
 
Glass and ceramic gel plates were sandwiched using a spacer and set up in a casting 
apparatus. The resolving gel solution was mixed to a 10% acrylamide concentration 
before adding TEMED (1.3mL 1.5M Tris pH 8.8, 1.7mL 30% acrylamide, 2mL ddH2O, 
50µL 10% SDS, 50µL 10% APS – per gel). Upon thorough mixing, 6µL TEMED added 
and solution was quickly pipetted into the glass/ceramic sandwich. About a centimeter 
was left between the top of the solution and the top of the gel plates. The resolving gel 
was allowed to polymerize. The stacking solution was mixed (260µL 1M Tris-HCl pH 
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6.8, 340µL 30% acrylamide, 1.36mL ddH2O, 20µL 10% SDS, 20µL 10% APS – per gel) 
and the TEMED was added (6µL) to polymerize. Stacking solution was poured on top of 
resolving gel until reaching the top of the plates, and a 10-well ladder was inserted into 
the stacking gel. After fully polymerizing, gel was removed from casting apparatus and 
moved to a gel running box. 1X SDS Running Buffer (188g Glycine, 10g SDS, 30.3g 
Tris base, ddH2O to 1L) was added to the exterior and interior chambers of the box, and 
the ladder was carefully removed from the gels. The lid to the box was attached, and the 
gel was run at constant 20mA until samples were ready to be loaded. Before loading, 
each well was rinsed using a syringe filled with 1X Running Buffer. Samples were 
loaded and gel was run at a constant 20mA for 30-90 min (depending on how many gels) 
or until the front edge of the sample made it to the bottom of the gel. Upon completion of 
the run, the gel plate sandwiches were removed, and carefully separated to reveal the gel. 
The stacking portion of the gel was cut off and discarded, and the resolving gel was left 
in Coomassie blue stain overnight at room temperature on a rotary shaker. The following 
day, gel was destained using a solution of 20% methanol, 10% glacial acetic acid until 
protein bands visible. 
 
Immunoblot for MBP 
 
Once SDS-PAGE gel had run to completion, the gel was removed from the plates, 
and the stacking gel was cut off. Gel was equilibrated in Towbin Transfer buffer (3.03g 
Tris Bas, 14.4g Glycine, 100mL 100% Methanol, ddH2O to 1L – stock solution). PVDF 
membrane was cut to 5.5x8.5cm and activated in 100% Methanol for 1min, followed by 
15min in Towbin Transfer buffer. Four filter papers were also cut to the same size and 
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equilibrated in Towbin Transfer buffer. The stack was then assembled on the bottom 
plate of the Bio Rad Semi-dry electro transfer apparatus with 2 filter papers, the PVDF 
membrane face up, the SDS-PAGE gel, and 2 more filter papers. Towbin Transfer buffer 
was then poured over the top to fully saturate the stack, and the lid was attached and run 
at constant 12V for 30min. The entire stack minus the PVDF membrane was then 
discarded, and the membrane was blocked in 50mL blocking buffer (5% nonfat dry milk 
[wt/vol] in 1X Tris-buffered saline supplemented with Tween-20 [TBST]) overnight at 
4°C on a rotary shaker. The next day, the blocking buffer was discarded, and 10mL of 
blocking buffer was added on to the membrane, and anti-MBP antibody [New England 
Biolabs, E8032S] was added in a 1:5000 concentration and incubated at 4°C overnight on 
a rotary shaker. The membrane was then washed 3x for 5min in 1X TBST, then 
secondary antibody [Abcam, ab97020, lot:GR3186575-6] was added in a 1:5000 
concentration and incubated for 1h at room temperature on a rotary shaker. Membrane 
then washed 3x for 5min in 1X TBST, and BCIP detection solution [Sigma, B3679, Lot: 
MKBZ5868V] was poured onto the membrane until completely covered. Once the 
membrane was properly exposed, water was poured over it to quench the reaction, and 
membrane was dried before being stored. 
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RESULTS 
 
Protein purification attempts failed to bind target protein on amylose beads 
 
Prior to large scale protein isolation from TOP10 E. coli strain expressing truncated 
CpsA with an MBP tag (MBP-CpsA-ΔLytR), preliminary testing was performed to 
identify sonication strength settings that were appropriate to release target protein via cell 
lysis. Sonication times were tested at a constant power setting in order to determine 
which setting was appropriately lysing the cells. Control CpsA and CpsA-ΔLytR samples 
were used from previous purification assays performed in 2012 (Neely lab, 2012). These 
samples were also tagged with MBP. Results from these controls indicated degradation 
from the intended protein size of around 70kDa (Fig. 10, lanes 2 and 3). Results indicated 
that more lysis was observed with a 5min sonication as opposed to 3 min, while 7- and 
10-min intervals did not show a significant increase based on visual inspection of SDS-
PAGE gels (Fig. 10, lanes 4-7). Immunoblot results were consistent in showing all 
samples were releasing MBP-tagged CpsA-ΔLytR.  
 
Preliminary Sonication of E. coli Containing MBP-tagged CpsA-ΔLytR 
 
70 kDa- 
55 kDa- 
40 kDa- 
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Figure 10. SDS-PAGE gel (A) and immunoblot for MBP (B) results from preliminary 
sonication testing of E. coli strain expressing MBP-CpsA-ΔLytR. Lane 1 is a molecular 
weight marker, lane 2 is an old sample of previously purified CpsA-MBP full length used 
as a control, lane 3 is a previously purified CpsA-MBP-ΔLytR used as a control, lane 4 is 
3 min total sonication, lane 5 is 5 min, lane 6 is 7 min, and lane 7 is 10 min. Red boxes 
around bands of interest indicate full length MBP-CpsA-ΔLytR from on the sonicated 
sample lanes at the desired weight. Strong bands at 70kDa in each of the sonicated 
samples (lanes 4, 5, 6, and 7) indicate that the protein is being released from the cell and 
is free in the lysate. Bands seen below 70kDa are degradation products from this protein, 
with the bottom band likely being the stable MBP protein, with all CpsA degraded. 
 
After small scale testing (amylose resin incubated with lysate in a microcentrifuge 
tube) indicated release of the desired protein, the sonicated lysate was applied to the 
amylose column (see column purification protocol) in an attempt to purify MBP-CpsA-
ΔLytR for use in a GBS lysate. After elution with maltose, 11 fractions were collected 
and analyzed via BCA Protein Assay. Concentration of protein was observed to be below 
the desired concentration, with all samples reading below 0.1µg/µL. Fractions were then 
concentrated via filter centrifugation; however, the resulting solution was too 
concentrated to read. It was then serially diluted by half five times in an attempt to reach 
a readable dilution. These dilutions were then resolved on a protein gel and 
immunoblotted in order to see if MBP-CpsA-ΔLytR was successfully isolated from the 
column purification protocol. These data are not shown here, as both Coomassie Blue R-
250 stained SDS-PAGE gel and immunoblot results indicated no detectable levels of 
protein present in any of the fractions. Faint immunoblot bands in the flow through 
sample for lysate that did not bind to the amylose beads is indicative that MBP-CpsA-
ΔLytR may not have bound at all to the column. This protocol of amylose column 
 29 
isolation was repeated, and samples were sonicated for 10 min, with no lysozyme 
solution, and again indicated no binding to the amylose column. None of the SDS-PAGE 
or immunoblot from any of the fractions of this column elution indicated any visible 
protein bands, or any detectable levels of MBP.  
Before moving on to the in vivo method of protein isolation, a small-scale amylose 
assay was run to verify that there was no binding under any tested conditions. This time, 
the lysis buffer was added prior to 7min sonication and addition of the amylose resin. 
Upon completion of the protocol and gel electrophoresis, it was discovered that there was 
again no binding to the amylose beads even when the raw lysate was shown to contain a 
significant amount of protein, indicative of successful cell lysis (Fig 11, lane 2). This 
method was attempted twice more, with careful attention paid to execution of the 
protocol, and samples saved at every step to indicate where there may be an issue. The 
final iteration of this small-scale protocol resulted in the same result as the previous 
attempts. SDS-PAGE and immunoblot for MBP from this protocol indicated that 
although the MBP-CpsA-ΔLytR was being successfully released from the membrane at 
least partially, there was very poor binding to the amylose beads (Fig. 12, lanes 5 and 6). 
This was evidenced by the fact that when the lysis was spun down after sonication, the 
structural debris from the cells which pelleted at the bottom still showed MBP-CpsA-
ΔLytR present, but its presence was also observed in the supernatant (Fig. 12, lanes 4 and 
5). From this point, the in vivo testing had begun, and this protocol was no longer 
attempted as it was clear there was very little binding to the beads which requires further 
troubleshooting before can be successfully used to pulldown the target MBP-CpsA-
ΔLytR. Suggestions for future efforts include using the finalized lysis protocol in order to 
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ensure entire cell lysis. It is also suggested to use fresh, non-regenerated amylose in order 
to maximize binding. One final suggestion would be to lower salt concentrations in the 
solution in order maximize binding potential, and to also reduce detergent levels while 
binding, as this could also be cutting down on interactions between the target protein and 
the amylose resin within the column. 
 
Small-Scale Amylose Pulldown Results 
 
 
Figure 11. SDS-PAGE gel of small-scale amylose pulldown to test viability of larger 
protein purification. Lane 1 is the Page Protein Plus Ladder [ThermoFischer #26619, lot 
00353954], lane 2 is the lysate after sonication and chemical lysis, lane 3 is eluent from 
this small-scale test, and lane 4 is eluent from the previously run larger scale column. 
Lane 2 indicates good lysis seen by numerous individual bands representing released 
proteins. Lane 3 indicates that there was no binding or elution from the small-scale test, 
as no protein bands are seen. Lane 4 also shows this result from the previously run large-
scale column, indicating that no protein was purified from either protocol. 
 
 
70 kDa- 
55 kDa- 
 
35 kDa- 
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Final Results from Small-Scale Amylose Pulldown Assay 
 
Figure 12. SDS-PAGE gel (A) and immunoblot for MBP (B) results from final iteration 
of small-scale amylose pulldown assay. Lane 1 is the ladder, lane 2 is the whole induced 
cell before lysis, lane 3 is the lysis after sonication, lane 4 is the spun down debris from 
the lysis, lane 5 is the flow through from incubation on the amylose bead, lane 6 is the 
bead itself after elution, and lane 7 is the eluted protein. Red box indicates band of 
desired weight protein on flow through and eluted sample (5 and 7). This band at 70kDa 
in lanes 5-7 is the desired MBP-CpsA-ΔLytR and seeing a strong band in the flow 
through (lane 5) indicates that it is not entirely binding to the bead. Although immunoblot 
bands are seen in lanes 6 and 7, the corresponding lanes in the SDS-PAGE gel do not 
show any detectable levels of protein, so concentrations of this binding must be low. 
 
 
ChromoTek MBP-Trap kit was unsuccessful in coimmunoprecipitating binding partners 
of MBP-CpsA-ΔLytR in vivo  
 
Once large-scale protein isolation progress indicated that it was unlikely to be 
unsuccessful in isolation of MBP-CpsA-ΔLytR, work began on an in vivo assay, which 
had been used previously in isolation of MBP-CpsA. This assay used an antiMBP-
70 kDa- 
55 kDa- 
40 kDa- 
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nanobody-coupled agarose bead to bind the target protein MBP-CpsA-ΔLytR. This 
protein could then be eluted to identify any proteins that bound along with it and were not 
washed away (Fig. 13). Due to the porous nature of the bead, there is often a significant 
amount of nonspecific binding, in which undesired proteins interact with the bead and 
could be mistaken for proteins that are interacting with the target. Because of this, it is 
important to take into account a negative control, in which a strain of GBS with no CpsA 
or MBP is put through the same assay, so any results that appear in both samples can be 
subtracted from the final result (Fig. 13). 
 
Diagram of In Vivo MBP- CpsA-ΔLytR Coimmunoprecipitation Assay  
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Figure 13. ChromoTek MBP-Trap kit diagram, indicating the workflow from cell growth 
through binding onto the nanobody-bound agarose bead. This model indicates the 
positive sample with MBP-CpsA-ΔLytR, and the negative control with no CpsA or MBP, 
with sample proteins modeled to indicate binding partners and nonspecific interactions 
with the agarose bead. 
 
Upon first completion of this protocol, with GBS cells being lysed solely using the 
lysozyme solution described previously, results from the SDS-PAGE gel revealed 
streaky, nonspecific banding with no clear pattern (Fig. 14, lanes 2 and 3). From this 
result it is unclear whether the cells were completely lysed given the streaky nature of the 
total protein lane considering DNA was eliminated using DNase 1 in the lysozyme 
solution (Fig. 14, lanes 2 and 3). This assay was also unable to resolve whether there was 
binding to the MBP-Trap beads, or if any binding was inhibited by lack of proper cell 
lysis. It is important to note that there was no preclear of lysate in nonspecific beads in 
this iteration of the protocol, and the beads were not pre blocked. Neither of these 
conditions should have impacted the ability of the protein to bind and would only cut 
down on nonspecific binding. In order to address this lack of binding, emphasis on the 
next experimental trials was placed on effective lysis of GBS cells. 
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Initial ChromoTek MBP-Trap Assay Results 
 
Figure 14. SDS-PAGE gel from initial ChromoTek MBP-Trap kit assay. Lane 1 
corresponds to the ladder, lane 2 is the negative control total protein, lane 3 is the MBP-
CpsA-ΔLytR total protein, lane 4 is the flow through from the beads of the negative 
control, lane 5 is the flow through from the MBP-CpsA-ΔLytR sample, lane 6 is the 
eluted protein from the beads of the negative control, and lane 7 is the eluted protein from 
the beads of the MBP-CpsA-ΔLytR sample. No distinct banding in any lanes indicates 
that there likely was no successful lysis, and all proteins were unable to be separated. 
Lanes 6 and 7 showing no bands at all also indicates that there was no binding to the 
beads or elution given the level of lysis. 
 
Further optimization of the MBP-Trap protocol in order to better lyse cells to allow 
binding to MBP-Trap beads resulted in establishment of a protocol that indicated positive 
results. In addition to the lysozyme solution previously used as a form of lysis, 1.5min of 
sonication was used to better break open cells and release the MBP-CpsA-ΔLytR from 
the peptidoglycan. Upon further testing, this iteration resulted in a blot that indicated 
70 kDa- 
 
55 kDa- 
 
40 kDa- 
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binding and elution from the MBP-Trap beads, as well as a difference in positive and 
negative samples (Fig. 15, lanes 5 and 6). When looking at the SDS-PAGE gel result 
from this assay, there is a difference in bands seen between the negative control with no 
CpsA present, and the MBP-CpsA-ΔLytR, indicating that proteins were being pulled 
down that were not just nonspecifically binding to the MBP-Trap bead (Fig. 15, lanes 5 
and 6). Immunoblot results from MBP confirm this result, with no significant levels of 
MBP being detected in any sample other than the eluted protein, and some residual MBP 
left on the beads that either was not eluted, or was in the insignificant amount of 
supernatant that was not properly pulled away from the beads (Fig. 15, lanes 6 and 7). 
This was the desired result of the assay, and upon repetition could be sent out for mass-
spec identification of coimmunoprecipitated proteins. 
 
Successful Coimmunoprecipitation of MBP- CpsA-ΔLytR Binding Partners using 
the ChromoTek MBP-Trap Assay 
Figure 15. SDS-PAGE and immunoblot result from later iteration of ChromoTek MBP-
Trap kit assay. Lane 1 is the ladder, lane 2 is the cell debris pellet from the MBP-CpsA-
ΔLytR sample, lane 3 is the total protein from the MBP-CpsA-ΔLytR sample, lane 4 is 
70 kDa- 
55 kDa- 
40 kDa- 
 36 
the total protein from the negative control, lane 5 is the final eluted protein from the 
negative control, lane 6 is the final eluted protein from the MBP-CpsA-ΔLytR sample, 
and lane 7 is the residual beads after elution from the MBP-CpsA-ΔLytR sample, with a 
red box indicating the visible bands in the immunoblot sample. A difference in protein 
bands seen in the SDS-PAGE gel in lanes 5 and 6 indicate that there are different proteins 
being bound to the negative control, and the MBP-CpsA-ΔLytR sample. The immunoblot 
results for these lanes indicate that there is a band at the desired 70kDa for the MBP-
CpsA-ΔLytR (red box around bands), which is not present in the negative control. 
 
This protocol was repeated again, and results indicated poor binding to the beads once 
again (data not shown). The protocol was repeated, and results were more indicative of 
binding to beads, although not as clearly as previous run, and the sample was sent off to 
mass-spec along with the full stained gel. Unfortunately, mass-spec results were 
inconclusive, with the same proteins found in both the positive and negative control 
samples. There is no data to show from the mass-spec analysis of the samples. 
From here, a switch was made in the protocol in an attempt to better isolate strictly 
desired proteins to avoid significant amounts of nonspecific binding. One last assay was 
run recently, however, in which the exact protocol of previous Neely lab member 
Danielle Steffey was run. Danielle was the student who previously conducted this assay 
in an attempt to isolate binding partners of CpsA wild type protein and was successful in 
doing so. The only differences in her protocol to mine was there was no sonication step, 
and after incubation in lysozyme solution, the lysate was incubated overnight on preclear 
beads that contained no MBP nanobody but were the same composition, which should 
clear any nonspecifically binding proteins from the lysate before incubation on the MBP-
Trap beads. A first test of this also used Glycine to elute proteins off of beads rather than 
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boiling, and a second test used boiling to elute as previously described. Upon completion 
of the protocol, and SDS-PAGE and immunoblot to detect MBP, both tests indicated 
insignificant amounts of protein bound to the MBP-Trap beads, and none seem to be 
eluted in any assay. It was unclear in these tests where the problem may lie, either in the 
lysis step or the binding step, and due to time constraints, no further assays could be 
performed. 
 
Anti-MBP tagged magnetic beads were also unable to coimmunoprecipitate binding 
partners of MBP-CpsA-ΔLytR when the switch was made from ChromoTek MBP-Trap 
beads 
 
Due to the failure of the ChromoTek MBP-Trap beads to successfully bind target 
proteins in the GBS lysate, a switch was made to using a new type of bead. The theory 
behind this assay remains the same, however the magnetic beads used are composed of a 
solid bead core, rather than porous agarose in the case of the ChromoTek assay, which 
should better bind target proteins only. It was hopeful that these new beads would also 
bind the MBP-CpsA-ΔLytR better, as it exhibited difficulty in binding to the ChromoTek 
MBP-Trap beads. Prior to testing this new bead with GBS strains, a preliminary test was 
run with E. coli expressing MBP-CpsA-ΔLytR in order to confirm binding to both Anti-
MBP magnetic beads, and magnetic beads with amylose resin. This also served as a way 
to familiarize myself with this new protocol before running the in vivo assay. After a few 
trial runs, results indicated that the protein expressed from E. coli cells was binding to the 
magnetic beads, indicating their viability for the in vivo assay (data not shown). A note: 
Due to the small-scale nature of this assay, this would not be an appropriate assay to 
purify MBP-CpsA-ΔLytR from E. coli, as amounts would be too low. 
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After running this assay using a GBS strain expressing MBP-CpsA-ΔLytR and a 
strain containing no CpsA or MBP (same strains as in ChromoTek assay), immunoblot 
results for MBP indicated very little binding to the beads, and not much MBP present in 
any of the samples. It became apparent from subsequent testing that the protein was not 
entirely being released from the cell membrane and was being spun down with the cell 
pellet after lysis, as evidenced by immunoblot results indicating strong levels of MBP in 
the cell pellet (Fig. 16, lane 7). This may have been impacting prior results when using 
ChromoTek MBP-Trap beads, however in this case there was even less binding on many 
of the tests than was seen previously, the reason for which is unknown. Indicated by the 
immunoblot, the only MBP detected from the MBP-CpsA-ΔLytR protein was in the spun 
down pellet from the MBP-CpsA-ΔLytR sample (Fig. 16, lane 7). This means that lysis 
was not entirely releasing the MBP-CpsA-ΔLytR from the cell wall, or if it was it was in 
undetectable quantities and the majority was remaining associated with the peptidoglycan 
and spun down into the pellet. 
 
Anti-MBP Magnetic Bead Analysis Assay to Determine MBP-CpsA-ΔLytR Location 
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Figure 16. SDS-PAGE and Immunoblot results from test assays to determine location of 
MBP-CpsA-ΔLytR following lysis protocol. Lane 1 is the ladder, lane 2 is the negative 
control lysate, lane 3 is the MBP-CpsA-ΔLytR lysate, lane 4 is the negative control 
supernatant after spin down, lane 5 is the MBP-CpsA-ΔLytR supernatant after spin down, 
lane 6 is the cell debris pellet from the negative control, and lane 7 is the cell debris pellet 
from the MBP-CpsA-ΔLytR. Immunoblot results show that the MBP-CpsA-ΔLytR is 
only seen in the cell pellet lane 7, indicated by an arrow, which indicates that the protein 
is not being released entirely from the cell membrane into the supernatant. 
 
From this point, with the understanding that the MBP-CpsA-ΔLytR was not being 
released for proper amounts for this assay, work continued on determining a protocol to 
effectively release the protein from the cell wall. This process went through a few 
iterations, however the protocol that was established to work consisted of overnight 
cultures used with no sub culturing, and used both the lysozyme solution (originally 
described in methods for GBS) for 2h at 37°C and the lysis solution (originally described 
in methods for E. coli) for 1h at 37°C. The sonication step was omitted, and upon running 
this new lysate through the magnetic bead protocol using just the anti-MBP tagged 
magnetic beads, results indicated successful binding and elution (Fig. 17, lanes 6 and 7). 
 
Anti-MBP Magnetic Bead Assay Results Following Successful Lysis 
 
70 kDa- 
55 kDa- 
40 kDa- 
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Figure 17. SDS-PAGE and Immunoblot results from magnetic Anti-MBP bead assay 
using new lysis protocol. Lane 1 is the ladder, lane 2 is the flow through that didn’t bind 
to the bead from the negative control, lane 3 is the flow through from the MBP-CpsA-
ΔLytR sample, lane 4 is the beads post-elution from the negative control, lane 5 is the 
beads post-elution from the MBP-CpsA-ΔLytR sample, lane 6 is the final protein eluted 
from the negative control, lane 7 is the final protein eluted from the MBP-CpsA-ΔLytR, 
and lane 8 is the Anti-MBP magnetic beads run with no protein bound as a control. 
Arrow indicates MBP-CpsA-ΔLytR at correct molecular weight in the MBP-CpsA-
ΔLytR eluted sample. This result shows that there is binding of the desired MBP-CpsA-
ΔLytR in the elution sample (lane 7) and not in the negative control (lane 6), however the 
SDS-PAGE result shows low concentrations of protein seen with the Coomassie Blue 
stain. There are also no distinct differences seen in the SDS-PAGE results between the 
negative control and the MBP-CpsA-ΔLytR sample. 
 
From this immunoblot result, it is apparent that there is significant amount of 
nonspecific secondary antibody binding, which was calculated for by running a control 
lane of just the beads with no protein (Fig. 17, lane 8). With this in mind, this 
immunoblot result also shows a significant amount of detectable MBP-CpsA-ΔLytR in 
the eluted sample, as evidenced by presence of a band at 70kDa, the expected location of 
this protein, which is also not visible in any other lanes except a small amount on the 
beads that was not eluted (Fig. 17, lane 7). This is a very promising result in achieving 
the goal of sending samples out for mass-spec, however although the band is present in 
the immunoblot, SDS-PAGE results for the negative control lane compared to the MBP-
CpsA-ΔLytR sample do not indicate observable differences, and are also very faint (Fig. 
17, lanes 6 and 7). This is much closer to the desired result; however, it is necessary to 
concentrate the lysate going on to the beads in an attempt to strengthen the signal seen on 
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SDS-PAGE result to ensure a difference in negative control bands to the MBP-CpsA-
ΔLytR sample. 
In an attempt to better coimmunoprecipitate binding partners so they stick to MBP-
CpsA-ΔLytR more definitively, and are not potentially lost during the assay process, 1% 
formaldehyde was added to the cells prior to lysis to crosslink proteins and quenched 
with 0.125M glycine. From here, the protocol was repeated exactly. Unfortunately, this 
did not give any result, and SDS-PAGE and immunoblot did not show any better result 
than the one shown previously, with faint bands shown on the eluted protein lanes (data 
not shown). To better concentrate proteins, after lysis the 2mL of supernatant was spun 
down using a 10 kDa spin column filter to 500µL. However, even combined with the 
formaldehyde crosslinking and this still did not yield any different results. Trying this 
protocol again with no formaldehyde crosslinking indicated more protein bound to and 
eluted off of beads, however still no difference in bands seen between negative control 
and the MBP-CpsA-ΔLytR sample.  
The final iteration of this protocol and the one that was run most recently used a 
2.75hr incubation in lysozyme solution followed by the lysis solution. The sodium 
phosphate wash was supplemented with 0.1% Triton X-100. Incubation on the Anti-MBP 
magnetic beads only continued for 1 hour as opposed to overnight, and subsequent wash 
also used the supplemented 0.1% Triton X-100 sodium phosphate. 
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Results from Anti-MBP Magnetic Bead Assay with Concentration of Lysates 
 
Figure 18. SDS-PAGE and immunoblot results from final iteration of anti-MBP 
magnetic bead protocol. Lane 1 is the ladder, lane 2 is the empty control flow through 
that didn’t bind to beads, lane 3 is the MBP-CpsA-ΔLytR flow through, lane 4 is the 
beads post-elution from the negative control, lane 5 is the MBP-CpsA-ΔLytR beads post-
elution, lane 6 is the final eluted protein from the negative control, and lane 7 is the final 
eluted protein from the MBP-CpsA-ΔLytR sample. Again, it is seen on the immunoblot 
that the desired 70kDa band of MBP-CpsA-ΔLytR is only seen in the proper samples and 
is seen as a strong band in the eluted sample (lane 7). When looking at the SDS-PAGE 
result, there is no distinction between protein bands in the negative control elution (lane 
6) and the MBP-CpsA-ΔLytR sample (lane 7). 
 
From this final assay, there was significantly increased binding, and elution off of the 
anti-MBP magnetic beads, as indicated by SDS-PAGE results showing clear banding for 
both elution samples (Fig. 18, lanes 6 and 7). However, there is no visible distinction 
again between the negative control bands, and the MBP-CpsA-ΔLytR sample bands, 
which is undesirable for mass-spec, where previously attempts showed that this would 
result in a loss of resolution of target proteins (Fig. 18, lanes 6 and 7). It is still confirmed 
that the MBP-CpsA-ΔLytR protein is correctly binding as well, as immunoblot results 
indicate its presence only in MBP-CpsA-ΔLytR samples. The only band at 70kDa seen 
70 kDa- 
55 kDa- 
 
40 kDa- 
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on the immunoblot is in these samples (Fig. 18, lanes 3, 5, 7), and all other immunoblot 
banding was previously shown to be caused by nonspecific binding from the anti-MBP 
magnetic beads (Fig. 17, lane 8). To date, this was the final assay performed using this 
protocol. Due to time constraints, work on this project has ceased for the time being.  
 
DISCUSSION 
 
 Even with the advances seen in antibiotic therapies in recent years, Group B 
streptococcus infections remain some of the most frequent causes of infant mortality. 
Infections in neonates and newborns cause outcomes like sepsis, premature birth, 
stillbirth, or meningitis [1]. Although treatable through use of beta-lactam antibiotics like 
Penicillin [1], this approach is unfavorable due to rapid development of antibiotic-
resistant strains [2,5]. Therefore, there is a clear need for development of specific 
therapies that can selectively target GBS without increasing risk of development of 
antibiotic resistant strains. 
 Recent studies into the virulence of GBS have indicated the polysaccharide 
capsule to be vital for survival from the host immune system, and penetration into 
normally sterile sites [5]. Removal of this capsule through genetic modification has 
resulted in attenuated forms of the bacteria when assayed using the zebrafish model [4]. 
One gene whose removal indicated decrease in capsule levels was cpsA, the 
multifunctional putative transcriptional regulator of the cps locus, the cluster of genes 
responsible for a number of proteins involved in capsule production and regulation. 
Although one function of the CpsA protein encoded by this gene is DNA-binding which 
is yet to be confirmed in GBS, the extracellular regions also contain numerous functions. 
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Containing two large domains, the Accessory and LytR domains, function of this region 
is less understood. Current studies indicate the LytR domain, which is seen as an 
independent protein in a number of Gram-positive pathogens, plays a role in the linking 
of polysaccharide polymers to the cell wall [10]. However, other functions of these 
domains remain to be understood. The goal of my project was to continue to elucidate 
function of the Accessory and LytR domains through coimmunoprecipitation of binding 
partners to a truncated form of CpsA.  
 Prior experiments conducted in the Neely lab generated a list of binding partners 
to the full length CpsA protein. These data returned a number of interesting proteins, 
including cell division protein FtsZ and additional proteins in the cps locus, among others 
(Neely lab, unpublished). However, it is currently unknown where these binding partners 
are interacting on the CpsA protein. A similar coimmunoprecipitation assay using a 
truncated form of CpsA can be used in order to better understand where each protein is 
interacting. The goal of this study was to run that assay and compare results from the 
truncated CpsA to the full-length form, which will give insight into the function of each 
of the extracellular domains. If the coimmunoprecipitation from the truncated CpsA 
returns the same proteins, it is apparent that they must be interacting with the Accessory 
or peptide region, and not LytR. If there are new proteins that are not seen on the full 
length coimmunoprecipitation data, it may be from proteins that are binding to the 
accessory or peptide region in the absence of LytR and possibly contributing to the 
dominant negative effect seen in strains expressing both CpsA full length, and CpsA-
ΔLytR. If any proteins are not seen in this result that were seen in the full length 
coimmunoprecipitation, it is likely that they are binding the LytR region. Using this 
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analysis, the function of the extracellular domains will start to be better understood once 
it is known specifically how they are interacting. From there, potential protein targets for 
novel therapeutic approaches can be identified and researchers will be a step closer to 
effectively treating GBS infections. 
 When performing these assays, changes were made from the previous protocols 
that resulted in the original list of CpsA binding partners. The reason for this was that 
when the full-length sample was sent out for mass spec, the returned list did not contain 
any CpsA (Neely lab, unpublished). This indicates that quantities of CpsA may have been 
low in the sample, a problem that was hoped to be overcome by modifying these 
protocols. It was for this reason that the initial attempts were made using the in vitro 
method, where the previous data was generated using the in vivo method. The idea there 
was that if MBP-CpsA-ΔLytR could be purified using an amylose column, it would be a 
simple matter to incubate this in a GBS lysate and then pulldown binding partners as 
described. Due to the thick cell wall, it was thought that this may be an inhibiting factor 
in the binding of CpsA to target proteins and to the pulldown beads (either the 
ChromoTek MBP-Trap beads or the New England Biolabs anti-MBP magnetic beads). 
Therefore, the in vitro assay was attempted first. 
 Unfortunately, after a number of attempts and iterations to the in vitro protocol, 
no successful protein purification was achieved. Although the first iteration of the 
protocol indicated no binding to the amylose beads in the column, it was believed the 
issue was grounded in the fact that the MBP-CpsA-ΔLytR was not being released from 
the E. coli successfully, leading to its loss when the cell debris was spun down. The 
following sonication assays to test whether the protein was being released resulted in a 
 46 
protocol that was shown to successfully release the MBP-CpsA-ΔLytR from the cell, so it 
was believed that this may increase binding to the amylose column and increase protein 
yields (Fig. 10). From here, the thought was that the protein would better bind to the 
amylose beads now that it was entirely released, and the MBP tag would be able to 
interact with the amylose. However, it was discovered through subsequent testing that 
although the protein was being successfully released, there was very little binding to the 
actual bead (Fig. 11, Fig. 12). It currently remains unknown as to why this was the result, 
and why the MBP tagged protein was flowing past the amylose beads without successful 
binding. Although not mentioned in the results section, multiple amylose bead slurry 
solutions were used in an attempt to rule out the possibility of a nonfunctioning bead. 
However, results did not improve. An extrapolation of a potential reason for this is 
discussed in the next paragraph. Some of the suggestions as mentioned previously were 
to decrease the salt concentration of the column buffer so as to allow for more binding, 
and to also decrease detergent concentration for the same reason, as it is hypothesized 
that these two aspects could be inhibiting MBP binding to the amylose resin of the 
column. The specifics of this troubleshooting is up to the discretion of the researcher, but 
these are a few factors that may have contributed to lack of biding in this iteration. Due to 
the time sensitive nature of this project, and the fact that this was only one of two 
methods planned to complete the goal, the in vitro testing was suspended as efforts 
shifted to focusing on the in vivo method.  
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Table of Salt Use in Each Step of Each Assay 
ASSAY SALT 
PRESENT 
FOR LYSIS 
SALT 
PRESENT 
FOR 
BINDING 
SALT 
PRESENT FOR 
WASHING 
SALT 
PRESENT 
FOR 
ELUTION 
LARGE-SCALE 
PROTEIN 
PURIFICATION 
150mM NaCl 
 
 
0.2M NaCl 
 
 
0.2M NaCl 0.2M NaCl 
SMALL-SCALE 
PROTEIN 
PURIFICATION 
150mM NaCl 
 
 
0.2M NaCl 
 
 
0.2M NaCl 
 
0.2M NaCl 
CHROMOTEK 
MBP-TRAP  
(ALL 
ITERATIONS) 
10mM MgSO4 
1mM CaCl2 
10mM MgSO4 
1mM CaCl2 
150mM NaCl 
(1x) 
500mM NaCl 
(2x) 
2% SDS 
NEB ANTI-MBP 
MAGNET 
BEADS 
(ITERATION 
#1) 
10mM MgSO4 
1mM CaCl2 
10mM MgSO4 
1mM CaCl2 
0.1M NaP 2% SDS 
NEB ANTI-MBP 
MAGNET 
BEADS 
(ITERATION 
#2) 
150mM NaCl 
 
 
150mM NaCl 
 
 
0.1M NaP 2% SDS 
Table 1. A summary of salt types and concentrations for each assay performed during 
this study. The table denotes which assay, and what specific type of salt was used in each 
step including lysis, binding, wash, and elution. 
 
 48 
Table of Detergent Use in Each Step of Each Assay 
ASSAY DETERGENT 
PRESENT 
FOR LYSIS 
DETERGENT 
PRESENT 
FOR 
BINDING 
DETERGENT 
PRESENT 
FOR 
WASHING 
DETERGENT 
PRESENT 
FOR 
ELUTION 
LARGE-SCALE 
PROTEIN 
PURIFICATION 
1% Triton X-
100 
10mM 
CHAPS 
1% wt/vol 
Sodium 
lauroyl 
sarcosinate 
0.2% Triton 
X-100 
2mM CHAPS 
0.2% wt/vol 
Sodium 
lauroyl 
sarcosinate 
None None 
SMALL-SCALE 
PROTEIN 
PURIFICATION 
1% Triton X-
100 
10mM 
CHAPS 
1% wt/vol 
Sodium 
lauroyl 
sarcosinate 
0.2% Triton 
X-100 
2mM CHAPS 
0.2% wt/vol 
Sodium 
lauroyl 
sarcosinate 
None None 
CHROMOTEK 
MBP-TRAP  
(ALL 
ITERATIONS) 
None None None None 
NEB ANTI-MBP 
MAGNET 
BEADS 
(ITERATION 
#1) 
None None None None 
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NEB ANTI-MBP 
MAGNET 
BEADS 
(ITERATION 
#2) 
1% Triton X-
100 
10mM 
CHAPS 
1% wt/vol 
Sodium 
lauroyl 
sarcosinate 
0.2% Triton 
X-100 
2mM CHAPS 
1% wt/vol 
Sodium 
lauroyl 
sarcosinate 
0.1% Triton X-
100 
None 
Table 2. A summary of detergent types and concentrations for each assay performed 
during this study. The table denotes which assay, and what specific type of detergent was 
used in each step including lysis, binding, wash, and elution. 
 
 
 When looking at the column purification attempt, the role of salts and detergents 
must be considered when trying to analyze why this process may have been unsuccessful. 
The basis of the purification assay is the MBP tag attached to the CpsA-ΔLytR will 
strongly bind to the amylose through hydrophobic interactions and hydrogen bonding. 
Use of salts in this assay can cut down on nonspecific interactions, thereby allowing only 
the MBP to bind to the amylose. Detergents can also play a role in cutting down on 
nonspecific interactions, or in aiding them by providing induced charges onto the protein, 
and solubilizing membrane proteins, which is applicable for the target protein here. They 
can also play a role in denaturing proteins through ionic binding, but this would depend 
on the ionic state of the detergent. For the column purification, the level of salt used 
remained constant and was determined through manufacturers protocols (Table 1). This 
level of salt could have been too high to allow specific binding, which could have 
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resulted in the results presented here. Inorganic salts such as NaCl can obstruct binding 
with their ionic properties resulting in what is called “shielding”, where the charge of the 
ion is blocked, which cuts down on low strength ionic bonding depending on the strength 
of the bond [12]. If this was the case in the column purification, and the level of salt was 
too high, the MBP may not have been allowed to properly bind to the amylose. Although 
not an ionic bond, the specific effects of the salt could have played a role here. Similarly, 
the detergents used could have denatured the protein to a point where it was unable to 
bind to the amylose, also resulting in decreased binding (Table 2). Therefore, it is 
recommended that a deviation be made to these aspects of the purification protocol for 
future work, in the hope that modifying the levels of both salt and detergent will promote 
MBP binding to the amylose column. 
 As is apparent from the results presented previously, neither the ChomoTek MBP-
Trap bead nor the New England Biolabs anti-MBP magnetic bead were successful in 
coimmunoprecipitating the binding partners for MBP-CpsA-ΔLytR. However, it is 
significant to note that the differences between the two methods were distinct, and that 
future work surrounding one or the other will differ. For the ChromoTek MBP-Trap 
bead, the issue seemed to lie in the ability of the protein to bind to the bead. Although 
work was done surrounding the lysis of the GBS cells, and a protocol was developed that 
seemed to successfully release the protein, there was a distinct lack of binding to the 
beads, and therefore no isolation or coimmunoprecipitation of the desired targets. Even 
after modifying this lysis protocol later on through work with the anti-MBP magnetic 
beads, this ChromoTek protocol still did not seem to work. However, it is significant to 
note that it did appear to work once, with a difference seen in the MBP-CpsA-ΔLytR 
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pulldown compared to the negative control with confirmation by immunoblot (Fig. 15). 
When rerun in order to confirm this result and send off for protein identification, it did 
not return the same result. In fact, this result was never replicated upon subsequent testing 
despite identical protocols. It is unsure of why this was the case, whether in the timespan 
between trials a reagent went bad, or whether small differences in the timing of steps 
resulted in protein degradation. Despite the inability to be replicated thus far, this stands 
as the most successful test run to date.  
 Looking again at the role that the salt and detergent levels played in the 
ChromoTek MBP-Trap protocol, they offer potential avenues for future research. Given 
that the issue with this protocol was a seeming lack of binding to the ChromoTek MBP-
Trap bead resin, it appears similar to the column purification issue discussed earlier. That 
similarity being that the MBP tagged target protein was not binding properly to the bead. 
It must be noted here that although binding was seen in one instance of this protocol in an 
appropriate manner, this result could never be repeated. The other times this protocol was 
run, binding was seen in significantly reduced amounts, which impacted the ability to 
complete this project. It is possible that the amount of salt used in this assay had an 
impact on the ability of the fusion protein to bind to the bead. The exact chemistry behind 
the bead composition is proprietary, so salt concentrations were used according to 
manufacturer protocol for the wash and elution steps. However, the lysis steps did 
contain salt that was varied from the wash steps (Table 1). This could, as discussed 
earlier, potentially impact the ability of the protein to bind to the bead through the 
shielding effect of the salt, or through some other mechanism as it interferes with the 
ability of the protein to form hydrophobic, hydrogen, or other interactions with its 
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binding partner, in this case the bead. Therefore, it is possible that by altering salt levels 
in the various steps, which has not been tried, binding of the MBP to the bead could be 
promoted. It is also important to note that no iteration with the ChromoTek MBP-Trap kit 
contained detergents (Table 2). It is also suggested that low levels of nonionic detergent 
(like Tween-20) be attempted instead of higher levels of salt to cut down on nonspecific 
binding. This would not impact the charges and conformation of the proteins, allowing 
the MBP to still bind as designed, however could reduce nonspecific binding in a 
different manner than the salt. This may have the effect of promoting binding as well. 
 When the switch was made to the New England Biolabs anti-MBP magnetic 
beads, the issue seemed to lie in the nonspecific binding to the beads from the negative 
control, where no MBP-CpsA-ΔLytR was present. As seen on SDS-PAGE results, there 
was no visible difference between the bands of the negative control, and the MBP-CpsA-
ΔLytR sample (Fig. 18). However, this result was confounded by the fact that there was 
an MBP-CpsA-ΔLytR band seen on immunoblot results for the same samples in the 
positive control, and not in the negative control (Fig. 18), indicating that the beads were 
specifically binding the target protein. It is worth noting that on these results there is a 
significant amount of background seen on the immunoblot results for both the negative 
control and MBP-CpsA-ΔLytR samples. Because of this, a test was performed where just 
the empty beads were resolved on an immunoblot in order to determine their ability in 
impacting the immunoblot results, and results were consistent with the background 
pattern seen in the samples (Fig. 17). However, because there was no distinct difference 
between visible band patterns on the SDS-PAGE, it was unclear whether target proteins 
were being pulled down. Before sending off to mass-spec for identification it was 
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important to ensure that results would return that contained a significant difference. If all 
results between the negative control and MBP-CpsA-ΔLytR sample were identical, it 
would be impossible to distinguish which proteins were binding to MBP-CpsA-ΔLytR, 
and which were just binding nonspecifically to the beads, therefore negating any result. 
Although a number of different tactics were used in an attempt to diminish this 
nonspecific binding on the negative control and to distinguish a difference between the 
two samples, nothing proved effective in doing so. This is discussed further in next 
paragraph. Due to time constraints, this was the final iteration of this project which has 
been suspended for the time being. 
 It is important to note that with the switch from the ChromoTek MBP-Trap bead 
to the NEB Anti-MBP bead, there were major differences not only seen in the binding 
and the background on the beads, but in the levels of salt and detergent used when lysing, 
binding, and washing the beads. Between the two different iterations of this protocol that 
were attempted, with the major variation being the lysis of the cells, there were major 
differences seen in the amount and type of both detergent, and salt used (Tables 1 and 2). 
The final iteration, which was the most successful, had issues with large amounts of 
nonspecific binding. It was shown through immunoblot results that the capture and 
elution of our target MBP-CpsA-ΔLytR was successful, yet SDS-PAGE results indicated 
high amounts of binding in the negative control as well (Fig. 18). Although these beads 
are advertised as containing no nonspecific binding, it is apparent that these proteins must 
be binding nonspecifically due to the lack of MBP-CpsA-ΔLytR seen in these samples. It 
was thought that if more detergent was added, specifically in the wash steps, this would 
cut down on the amount of proteins seen here due to the ability of the detergent to block 
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nonspecific binding by adhering to the target protein and preventing weak interactions. 
This should have resulted in fewer proteins binding due to the blocking action of the 
detergent, and for binding to occur, the two partners would have to have a much closer 
interaction. However, this did not seem to make an appreciable impact on the results. The 
lysis protocol for this iteration also contained significantly more detergent, and salt, as it 
was the combination of both prior lysis solutions. Unfortunately, it is currently unknown 
why there was so much nonspecific binding, especially due to the fact that these were 
nonporous beads with a specific MBP nanobody attached. Therefore, although this 
protocol was adapted with multiple attempts using varying levels of salt and detergent 
(Tables 1 and 2) it is likely not optimized for this fusion protein. A brief note, this 
protocol was also attempted with formaldehyde crosslinking, which solidifies the bonds 
between closely interacting binding partners, however this had no appreciable impact on 
the results. To conclude this discussion in the context of the NEB Anti-MBP Magnetic 
Beads, it is likely that there exists an optimal detergent/salt level that would result in 
minimal nonspecific binding due to reasons discussed previously. However, it was not 
identified during the course of this project. A suggestion based on the results here would 
be to increase detergent concentrations in the earlier steps of the binding, and to increase 
salt concentrations in the later washes where there were lower concentrations. This may 
cut down on nonspecific binding now that it is shown there is proper binding of the 
fusion protein. 
 Although no list of binding partners of MBP-CpsA-ΔLytR was generated from 
this project, valuable insight was gained into how to best coimmunoprecipitate binding 
partners for this construct. It was learned how to better release the target protein from the 
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cell wall which will improve future work using this protein. Numerous challenges were 
also overcome in the execution of various coimmunoprecipitation protocols. Despite no 
protocol working to completion, valuable steps were taken in the progress of this project, 
and from here it should be a simple matter of completing this project if desired. The 
ChromoTek protocol has shown that it has the ability to work as intended. In the future, 
that protocol can be used to likely complete this project. Although current conditions 
never did work as desired, it was shown to be very close to work, and had the switch not 
been made to the New England Biolabs protocol in an attempt to troubleshoot, it is likely 
that the project would have been completed using the ChromoTek protocol. However, in 
switching, valuable information was gained about the anti-MBP magnetic beads which 
initially seemed to improve results but were then shown to be ineffective in achieving the 
desired result. To conclude, although no list of binding partners was generated for MBP-
CpsA-ΔLytR, this project allowed protocols to be streamlined for future work. The Neely 
lab will continue to work towards the goal of understanding the mechanism behind CpsA. 
Current efforts in collaboration with The Jackson Laboratory to create a novel anti-CpsA 
antibody, combined with the insights gained from this project, have potential to quickly 
yield new data regarding the function of the extracellular domains of CpsA, putting us 
one step closer to creating a novel therapeutic approach to better combat GBS infections.  
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